Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients.

Kruser TJ, Traynor AM, Wheeler DL.

Expert Opin Investig Drugs. 2011 Feb;20(2):305-7. doi: 10.1517/13543784.2011.550873. Epub 2011 Jan 5. Review.

PMID:
21204748
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ.

J Clin Oncol. 2010 Oct 20;28(30):4609-15. doi: 10.1200/JCO.2010.30.5474. Epub 2010 Sep 20.

PMID:
20855820
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G.

J Clin Oncol. 2010 Mar 10;28(8):1387-94. doi: 10.1200/JCO.2009.25.4029. Epub 2010 Feb 8.

PMID:
20142592
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS.

J Thorac Oncol. 2013 Nov;8(11):1434-7. doi: 10.1097/JTO.0b013e3182a47162.

PMID:
24128713
[PubMed - indexed for MEDLINE]
5.

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.

Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA.

J Thorac Oncol. 2011 Jun;6(6):1128-31. doi: 10.1097/JTO.0b013e3182161508.

PMID:
21623279
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.

Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R.

Oncotarget. 2013 May;4(5):772-84.

PMID:
23800712
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.

Lu H, Wang L, Gao W, Meng J, Dai B, Wu S, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B.

Mol Cancer Ther. 2013 Dec;12(12):2864-73. doi: 10.1158/1535-7163.MCT-13-0233. Epub 2013 Oct 15.

PMID:
24130049
[PubMed - indexed for MEDLINE]
8.
9.

Dasatinib: an anti-tumour agent via Src inhibition.

Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V.

Curr Drug Targets. 2011 Apr;12(4):563-78. Review.

PMID:
21226671
[PubMed - indexed for MEDLINE]
10.

A phase 2 trial of dasatinib in advanced melanoma.

Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M.

Cancer. 2011 May 15;117(10):2202-8. doi: 10.1002/cncr.25766. Epub 2010 Nov 29.

PMID:
21523734
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.

Ceppi P, Papotti M, Monica V, Lo Iacono M, Saviozzi S, Pautasso M, Novello S, Mussino S, Bracco E, Volante M, Scagliotti GV.

Mol Cancer Ther. 2009 Nov;8(11):3066-74. doi: 10.1158/1535-7163.MCT-09-0151. Epub 2009 Oct 27.

PMID:
19861409
[PubMed - indexed for MEDLINE]
Free Article
12.

A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, Kratzke RA, Vokes EE; Cancer and Leukemia Group B (CALGB).

J Thorac Oncol. 2010 Mar;5(3):380-4. doi: 10.1097/JTO.0b013e3181cee36e.

PMID:
20087228
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.

Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM.

Invest New Drugs. 2012 Aug;30(4):1575-84. doi: 10.1007/s10637-011-9732-3. Epub 2011 Sep 1.

PMID:
21881918
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.

Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S, Blackwell KL.

Clin Cancer Res. 2011 Sep 15;17(18):6061-70. doi: 10.1158/1078-0432.CCR-11-1071. Epub 2011 Aug 2.

PMID:
21810917
[PubMed - indexed for MEDLINE]
Free Article
15.

Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM.

Sci Transl Med. 2012 May 30;4(136):136ra70. doi: 10.1126/scitranslmed.3003513.

PMID:
22649091
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Gefitinib therapy for non-small cell lung cancer.

Birnbaum A, Ready N.

Curr Treat Options Oncol. 2005 Jan;6(1):75-81. Review.

PMID:
15610717
[PubMed - indexed for MEDLINE]
17.

Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.

Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ.

Clin Cancer Res. 2011 Nov 1;17(21):6905-13. doi: 10.1158/1078-0432.CCR-11-0288. Epub 2011 Oct 25.

PMID:
22028489
[PubMed - indexed for MEDLINE]
Free Article
18.

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.

Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB.

Cancer Res. 2006 Jun 1;66(11):5542-8.

PMID:
16740687
[PubMed - indexed for MEDLINE]
Free Article
19.

A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo.

Ling C, Chen G, Chen G, Zhang Z, Cao B, Han K, Yin J, Chu A, Zhao Y, Mao X.

Int J Cancer. 2012 Nov 15;131(10):2411-9. doi: 10.1002/ijc.27504. Epub 2012 Mar 28.

PMID:
22362357
[PubMed - indexed for MEDLINE]
20.

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.

Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA.

Cancer. 2011 May 15;117(10):2112-9. doi: 10.1002/cncr.25769. Epub 2010 Nov 29. Erratum in: Cancer. 2012 May 1;118(9):2560. Johnson, Faye M [added].

PMID:
21523723
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk